As the transcription of PTEN can be activated by p53, the degradation of which is mediated by TG2 in RCC, the aberrant activation of mTOR observed in many RCC patients might be defined by a TG2-dependent mechanism. The gene discussed is MTOR; the disease is renal cell carcinoma.